- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05189158
Ventilatory Responses to Hypercapnic and Hypoxic Conditions in Hyperventilants
For almost a century, many hypotheses have converged on the idea of altered chemosensitivity in patients suffering from hyperventilation syndrome (HVS).
Given the evolution of current technical equipment and the ability to maximise true positives in HVS ( using the revised hyperventilation provocation test), it seems reasonable to investigate central and peripheral chemosensitivities in HVS subjects.
Study Overview
Status
Conditions
Detailed Description
In the inter-war period, many medical investigators who studied the hyperventilation syndrome (HVS) had already questioned the chemosensitivity to CO2 in HVS patients, without being able to explore it for all intents and purposes.
It was subsequently observed that although HVS is not systematically linked to manifest resting hypocapnia, it is nevertheless systematically correlated with significant variability and complexity of ventilation.
This is consistent with the observations of an increased plant gain in HVS, to be related to an increased loop gain (due to instability of controller gain feedback).
On the other hand, some authors already noted that, when capnia is chronically compromised in HVS, it can be greatly altered by small, transient and barely perceptible increases in VE: a 10% increase in VE could indeed halve PetCO2, while a sigh would be able to decrease PetCO2 by up to 15mmHg.
More recently, teh assumption was made that peripheral chemosensitivity may be impaired in HVS patients.
For all these considerations, it seems reasonable to investigate central and peripheral chemosensitivities in identified HVS subjects on the basis of an objective test, such as the induced hyperventilation test.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Brabant
-
Bruxelles, Brabant, Belgium, 1000
- Chu St Pierre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A plethysmography within subject's predicted values
- A negative metacholine test (no documented allergy)
- A hyperventilation provocation test result that is consistent with the Nijmegen questionnaire score, confirming either group classification (HVS+ or HVS-)
Exclusion Criteria:
- Each of the following known or documented conditions: chronic bronchitis (COPD), emphysema, asthma, cardiac disorder, neurological disorder, gastrointestinal disorder, thyroid disorder or psychological/psychiatric disorder
- Suspicious cardio-pulmonary exercise testing (CPET) with cardiac or respiratory limitation
- Pregnant women or women in the process of becoming pregnant
- Persons with a diving practice (amateur or professional),
- High-level athletes,
- Active smokers and
- persons using morphine, and/or barbiturates, and/or anxiolytics and/or sleeping pills
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: HVS-
subjects with no complaint AND a Nijmegen questionnaire score of < 23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS-)
|
The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs. By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear.
The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2.
Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
|
Other: HVS+
subjects with complaints AND a Nijmegen questionnaire score of ≥23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS+)
|
The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs. By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear.
The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2.
Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The slope of the ventilatory response to hypercapnia (HCVR)
Time Frame: baseline - during the test
|
Ventilation increase (litres/min) per unit increase in PetCO2 (mmHg) using Read's method
|
baseline - during the test
|
The slope of the ventilatory response to hypoxia (HOVR)
Time Frame: baseline - during the test
|
Ventilation increase (litres/min) per unit decrease in SpO2 (%) using Read's method
|
baseline - during the test
|
Ventilatory recruitment threshold (VRT) of the HCVR
Time Frame: baseline - during the test
|
From the average baseline ventilation and PetCO2, the VRT id the PetCO2 level at which the ventilatory response is activated
|
baseline - during the test
|
Ventilatory recruitment threshold (VRT) of the HOVR
Time Frame: baseline - during the test
|
From the average baseline ventilation and SpO2, the VRT is the level of SpO2 at which the ventilatory response is activated
|
baseline - during the test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extrapolated apnoeic threshold of the HCVR
Time Frame: baseline - during the test
|
PetCO2 level above which apnoea (zero ventilation) is disrupted, obtained from the extrapolation of the HCVR at the X-axis intersection (when VE=0 l/min)
|
baseline - during the test
|
Dyspnea
Time Frame: baseline, end of the test
|
Visual analogic scale (VAS) of dyspnea, from 0 (no dyspnea) to 10 (maximal dyspnea)
|
baseline, end of the test
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B076201836758 -2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxia
-
Western University, CanadaUnknownBrain Hypoxia IschemiaCanada
-
Yale UniversityTianjin Chest HospitalCompletedBrain Ischemia Hypoxia | Muscle; Ischemic | Muscle HypoxiaChina
-
Fliegerärztliches InstitutCompleted
-
University of Texas at AustinCompletedIntermittent HypoxiaUnited States
-
Owlet Baby Care, Inc.Completed
-
Robert L. OwensCompletedIntermittent HypoxiaUnited States
-
Montreal Heart InstituteUniversité de MontréalCompleted
-
United States Army Research Institute of Environmental...University of Puget SoundRecruiting
-
The University of Hong Kong-Shenzhen HospitalRecruiting
-
Sherief Abd-ElsalamRecruiting
Clinical Trials on Hypercapnic hyperoxic ventilatory response
-
Karolinska University HospitalCompletedHypoxia | Hypercapnia | Conscious Sedation | AnestheticsSweden
-
University of British ColumbiaCompletedHypoxia | Sleep Disordered Breathing | Respiration; Sleep Disorder | Chemoreceptor ApneaCanada
-
Radboud University Medical CenterRecruiting
-
Wissenschaftliches Institut Bethanien e.VPhilips RespironicsCompletedObesity Hypoventilation Syndrome (OHS)Germany
-
Leiden University Medical CenterDemconCompletedDiabetes Mellitus, Type 2 | HypoxiaNetherlands
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Hospital del Trabajador de SantiagoUnknown
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)CompletedInfant,PrematureUnited States
-
University of Missouri-ColumbiaMayo Clinic; National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Sleep Apnea | Vasodilation | VasoconstrictionUnited States